SeromYx was founded in July 2019 as a specialist Contract Research Organization to commercialize the Systems Serology platform, which incorporates 12 high throughput assays and machine learning computational analysis. This platform was developed by Dr. Galit Alter at the Ragon Institute of Harvard/MIT/MGH, with the support of DARPA and the Bill and Melinda Gates Foundation. SeromYx operates on a fee for service CRO business model with no entanglement of client IP.
Our platform measures Fc mediated antibody effector functions via recruitment of innate immune cells to drive clearance of a pathogen, infected cell, or tumor cell. Overall, we determine what function or combination of functions drives efficacy. By understanding features associated with protection, we help pharmaceutical and biotechnology companies design future vaccines and immunotherapies that specifically elicit those functions to make better products.
Use our proprietary tools to provide our clients with unprecedented insight into immune function so that they can discover and develop better vaccines, immunotherapies, drugs and diagnostics.
Our platform is applicable to many prophylactic and therapeutic areas, targets and indications and we are the only CRO with this extensive an assay breadth. Each project is customized to the specific client needs. Prior to starting work our subject matter experts consult on specific project requirements via scoping calls. Customized project proposals align objectives, milestones and deliverables. Projects are actively managed and executed by project managers via collaborative data-driven meetings.